Skip to main content

Table 2 Change in MRI parameters from baseline to Year 3 by IFN β-1a dosage

From: Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study

  MRI Parameter
  T2 lesion volume T1 Gd+ lesion volume T1 black hole volume
  IFN β-1a, 22 μg sc tiw IFN β-1a, 44 μg sc tiw IFN β-1a, 22 μg sc tiw IFN β-1a, 44 μg sc tiw IFN β-1a, 22 μg sc tiw IFN β-1a, 44 μg sc tiw
Absolute change, mm 3
   N 72 86 70 84 71 85
   Mean (SD) −174.9 (1609.8) −1037.2 (3863.3) −23.5 (198.5) −68.8 (316.3) 64.5 (608.5) −196.5 (1311.9)
   Median −81.6 −169.7 0.0 0.0 0.0 −25.3
   Q1, Q3 −654.5, 126.8 −1133.3, 13.5 0.0, 0.0 0.0, 0.0 −40.3, 92.5 −209.4, 26.8
   P value 0.092 0.472 0.017
Percentage change
   N 72 86 15* 19* 59* 73*
   Mean (SD) −4.5 (27.3) −10.2 (38.9) −54.2 (177.5) −65.4 (127.9) 10.3 (49.3) −7.8 (79.1)
   Median −3.4 −12.1 −100.0 −100.0 1.5 −16.1
   Q1, Q3 −14.5, 4.3 −30.6, 2.8 −100.0, −100.0 −100.0, −100.0 −10.6, 23.2 −50.5, 19.0
   P value 0.025 0.495 0.002
  1. Gd+, gadolinium-enhancing; IFN, interferon; sc, subcutaneously; tiw, three times weekly.
  2. *Percentage change was not calculated for patients with a lesion volume of 0 mm3 at baseline.